Compare ZWS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | COGT |
|---|---|---|
| Founded | 1900 | 2014 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.6B |
| IPO Year | 2008 | 2018 |
| Metric | ZWS | COGT |
|---|---|---|
| Price | $49.34 | $39.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $53.67 | $36.21 |
| AVG Volume (30 Days) | 894.8K | ★ 2.9M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,530,500,000.00 | $7,871,000.00 |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $5.13 | $1,733.58 |
| P/E Ratio | $140.46 | ★ N/A |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $35.73 | $9.13 |
| 52 Week High | $53.76 | $43.73 |
| Indicator | ZWS | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 73.49 |
| Support Level | $49.23 | $37.54 |
| Resistance Level | $51.65 | $40.62 |
| Average True Range (ATR) | 1.28 | 1.54 |
| MACD | 0.00 | 0.50 |
| Stochastic Oscillator | 28.24 | 92.31 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.